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Abstract
BACKGROUND: Surviving cells may repopulate tumors between courses of chemotherapy, thereby reducing the
effectiveness of treatment. Using a novel quantitative method, we characterize the influence of the tumor micro-
environment on repopulation of surviving cells in human tumor xenografts after paclitaxel treatment and evaluate
the potential of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, to inhibit repopulation. METHODS:
High-EGFR-expressing A431 xenografts and low-EGFR-expressing MCF-7 xenografts were treated with paclitaxel
or gefitinib. Time-dependent changes in cell proliferation (Ki67) and apoptosis (cleaved caspase 3) in relation to
total and functional tumor blood vessels (recognized by CD31 and a flow marker), and regions of hypoxia (recog-
nized by EF5) were quantified using fluorescence microscopy. RESULTS: Decrease in functional tumor vasculature
and in cell proliferation and increase in apoptosis were observed in A431 xenografts after treatment with either
paclitaxel or gefitinib. There was a rebound in functional vasculature and cell proliferation ∼12 days after treatment
with paclitaxel, and repopulation was observed from tumor cells close to regions of hypoxia. Cell proliferation
increased ∼5 days after the last dose of gefitinib. There were minimal effects of paclitaxel or gefitinib on cell pro-
liferation, cell death, or tumor vasculature in MCF-7 xenografts. CONCLUSIONS: Repopulation in A431 xenografts
after treatment with paclitaxel was associated with changes in functional tumor vasculature. Gefitinib decreased
cell proliferation in EGFR-overexpressing tumor xenografts, suggesting its potential to inhibit repopulation when
used in sequence with chemotherapy.
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Introduction
Limited studies have shown that surviving cells can repopulate a
tumor between courses of chemotherapy [1–3], but little is known
about the microenvironment in which cells repopulate within a solid
tumor. The tumor microenvironment is composed of components
that influence cell growth and cell death, including the tumor vas-
culature and regions of hypoxia. These factors allow for differing
gradients in oxygenation, nutrients and pH, which influence the
proliferation of cells within the tumor. In untreated tumors, cells
proximal to functional blood vessels have a higher rate of prolifera-
tion than more distal tumor cells, most likely owing to better avail-
ability of nutrients and oxygen close to functional vasculature [2–5].
Many chemotherapeutic agents target selectively cells that are rapidly
proliferating, and most drugs achieve a higher concentration close
to blood vessels [4]; therefore, cells closer to blood vessels are more
likely to be killed after chemotherapy.
Regions further from blood vessels contain viable tumor cells that
may be spared by chemotherapy; these cells might repopulate the
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tumor if their nutrition improves after death and removal of more
proximal cells. We hypothesize that repopulation will occur predom-
inantly from regions of solid tumors distal from the vasculature after
chemotherapy. In support of this hypothesis, Huxham et al. [2]
showed that tumor cells in human colon cancer xenografts began
proliferating in regions distal to blood vessels approximately 6 days
after treatment with gemcitabine. However, repopulation has not
been studied in other xenografts or human tumors or after treatment
with different chemotherapeutic agents, including those that affect
the tumor vasculature.
Many microenvironmental factors can influence the repopulation
of tumor cells within a solid tumor. Changes in tumor vasculature
can modify nutrient and oxygen gradients, thereby affecting the
distribution of proliferating cells and dying cells within the tumor.
Targeting the tumor vasculature can have both beneficial and detri-
mental effects—decreasing the tumor vasculature can limit the supply
of nutrients and oxygen to tumor cells thereby leading to antitumor
effects; however, decreased vasculature can also limit access of tumor
cells to anticancer agents administered through the bloodstream [6–8].
Hypoxia also has a paradoxical effect on tumor growth. Prolonged or
sustained hypoxia can result in cell death [9,10]; however, some tumor
cells exposed to hypoxia might also acquire mutations that could lead to
a more aggressive phenotype [10]. Because many anticancer agents have
effects on the tumor microenvironment, it is imperative to understand
how these factors contribute to repopulation within solid tumors.
Here we describe a novel method to quantify immunohistochem-
ical staining in tumor sections to characterize changes in the distribu-
tion of repopulation within solid tumors. Our protocol differs from
other methods in that it quantifies changes in immunohistochemical
staining in the whole tumor section, rather than selecting areas of
interest within a tumor; and it allows us to quantify cell proliferation
and cell death as binary measurements. Therefore, we are able to
reduce selection bias and account for heterogeneity in the tumor
microenvironment. Specifically, the present study aims to: 1) charac-
terize repopulation in A431 xenografts, a human squamous cell
carcinoma that overexpresses the epidermal growth factor receptor
(EGFR), and in low-EGFR-expressing MCF-7 xenografts, after treat-
ment with paclitaxel; 2) determine the potential of gefitinib to inhibit
repopulation; and 3) characterize changes in functional tumor vascu-
lature and tumor hypoxia after treatment with chemotherapy. Our
hypotheses are that repopulation will take place largely from poorly
nourished cells distal from functional vasculature and that gefitinib will
inhibit specifically repopulation in EGFR-overexpressing xenografts.
Materials and Methods
Cell Lines
Experiments were performed using the human vulvar epidermoid
carcinoma cell line A431 (reported to overexpress EGFR) and the
human breast carcinoma cell line MCF-7 (reported not to overexpress
EGFR) [11]. A431 cells were purchased from the American Type
Culture Collection (Manassas, VA). A431 cells were maintained
in Dulbecco modified Eagle medium supplemented with 10% fetal
bovine serum (HyClone, Logan, UT), and MCF-7 cells were grown
in α-minimum essential medium with 10% fetal bovine serum. Cells
were grown in a humidified atmosphere of 95% air/5% CO2 at 37°C.
Routine tests to exclude mycoplasma were performed. Expression of
EGFR was confirmed by immunohistochemistry (Figure W1) using
the mouse anti–human EGFR (Clone 31G7) antibody (Zymed
Laboratories, San Francisco, CA).
Drugs and Reagents
Gefitinib (Iressa) was provided by AstraZeneca (Macclesfield,
Cheshire, United Kingdom). Gefitinib was dissolved in 100% dimethyl
sulfoxide (Fisher Scientific, Pittsburgh, PA) to make a 1-mg/ml stock
solution, which was stored at 4°C; for in vivo studies, the stock solution
was diluted in phosphate-buffered saline and 10%SolutolHS 15 (BASF
Chemical Co, Ludwigshafen, Germany). Paclitaxel was purchased from
the hospital pharmacy as a 6-mg/ml stock solution and stored at room
temperature. EF5 was provided by the National Cancer Institute,
and Cy5-conjugated mouse anti-EF5 antibody was purchased from
Dr. Cameron Koch, University of Pennsylvania, PA. EF5 powder was
dissolved in distilled water and 2.4% ethanol and 5%dextrose tomake a
10-mM stock solution that was stored at room temperature. DiOC7
was purchased from AnaSpec Inc. (San Jose, CA) and a stock solution
(2.5 mg/ml) was made by dissolving in dimethyl sulfoxide. The stock
was diluted 1:10 in phosphate-buffered saline and 10% Solutol HS 15.
Effect of Paclitaxel and Gefitinib on Growth of Xenografts
Female athymic nude mice (4-6 weeks old) (Harlan Sprague-
Dawley, Madison, WI) were injected subcutaneously in both f lanks
with 1 × 106 A431 cells or 4 × 106 MCF-7 cells per side; before
injection of MCF-7 cells, mice were implanted with 17β-estradiol
tablets (60-day release; Innovative Research of America, Sarasota,
FL). There were five mice per treatment group (10 tumors), and each
experiment was repeated. Two perpendicular diameters were mea-
sured with a caliper, and once tumors reached a diameter of 5 to
8 mm, treatment commenced. Tumor volume was estimated using
the formula: 0.5(ab2), where a and b are the longer and shorter
diameters, respectively.
To determine effects of paclitaxel, mice were treated intraperitone-
ally (i.p.) once every 5 days for a total of three doses of 0, 10, 20, or
30 mg/kg body weight. To test the effects of gefitinib alone, doses of
50 or 100 mg/kg were administered by oral gavage daily for 3 d/wk
for 2 weeks. Tumor size and body weight were measured every other
day until tumors grew to a maximum diameter of 1.5 cm or caused
ulceration, when mice were killed humanely. To avoid bias, mice
were ear tagged and randomized, and measurements were made with-
out knowledge of the treatment history.
Effect of Paclitaxel and Gefitinib on Cell Proliferation
and Apoptosis
Mice with tumors of 5 to 8 mm in diameter were treated with
paclitaxel alone (a single 25-mg/kg dose administered i.p. on day 0)
or gefitinib alone (a dose of 100 mg/kg administered by oral gavage
daily for 3 days). Mice were killed humanely, and tumors were excised
on days 0, 2, 4, 6, 8, 10, and 12. There were three to five mice per
time point in both the paclitaxel or gefitinib treatment groups. The
hypoxia-selective agent EF5 (0.2 ml of 10 mM stock solution) was
injected i.p. ∼2 hours before killing the mice, and the perfusion
marker DiOC7 (1 mg/kg) was injected intravenously 1 minute before
killing the mice. Tumors were excised, immersed in OCT compound,
and frozen in liquid nitrogen. Tumors were cut into 10-μm-thick
sections and imaged using an Olympus BX50 fluorescence (Olympus,
Center Valley, PA) and bright-field microscope equipped for whole-
slide imaging using tiling and stitching.
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Tumor sections were first imaged for the perfusion marker DiOC7
using an fluorescein isothiocyanate filter set. Sections were then
stained for blood vessels using a rat anti-CD31 primary antibody
(BD Biosciences, Toronto, Canada) and Cy3-conjugated goat anti-
rat IgG secondary antibody. Hypoxic regions were identified using
a Cy5-conjugated mouse anti-EF5 antibody, proliferating cells were
stained for Ki67 (rabbit anti–human Ki67 antibody, HRP chromo-
gen; Novus, Oakville, Canada), and apoptotic cells were stained for
cleaved caspase 3 (rabbit anti–human cleaved caspase 3 antibody,
HRP chromogen; Cell Signaling, Danvers, MA). Tumor sections
were imaged for CD31 using the Cy3 filter set, and EF5 was imaged
using the Cy5 far-red filter set. Ki67 and cleaved caspase 3 were im-
aged using transmitted light.
Image Analysis and Quantification
Microscope images of tumor vasculature and hypoxia were quantified
using Media Cybernetics Image Pro PLUS software (Bethesda, MD).
A threshold was used to select pixels occupied by blood vessels, as
represented by CD31 staining, and the image was binarized by setting
these blood vessel regions to white (pixel value, 255) and background pix-
els to black (pixel value, 0) to form a “mask” of positive CD31 staining.
Using Image Pro’s Count/Size tool, objects with a pixel intensity of 255
(i.e., CD31-positive) were counted in each tumor section. The tumor
area (excluding areas of necrosis or artifacts) was measured using Image
Pro’s calibrated area measurement tool. The mean number of total blood
vessels per tumor area was calculated. A similar method was used to
evaluate functional blood vessels: the total number of objects in DiOC7
binarized images was counted and the number of DiOC7-positive ob-
jects was divided by the number of CD31-positive objects to provide
an estimate of the proportion of functional vessels in each tumor section.
Total vasculature includes all blood vessels stained by CD31, whereas
functional tumor vasculature includes only those vessels that have func-
tional blood flow (as measured by the perfusion marker DiOC7).
Hypoxia was evaluated by setting a threshold on the EF5 image
and using Image Pro’s Count/Size tool to determine the total area
of pixels selected by the threshold. The percentage of hypoxia was
Figure 1. (A) Grayscale image showing gradient of pixel distances in relation to the nearest functional blood vessel (white = farthest
distance from blood vessel, black = location of blood vessel). (B) Color composite of the gradient of pixel distances shown in panel A
(pseudocolored green) and the blood vessel marker (binarized and pseudocolored red). (C) Distance image of a tumor section showing
gradient of distance units corresponding to all Ki67/cleaved caspase 3–positive pixels (grayscale image: white represents farthest dis-
tance from blood vessel and black represents a distance unit of zero)—similar methods were used for quantifying cleaved caspase 3.
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calculated by taking the area of EF5-positive staining and dividing it
by the total tumor area. We did not attempt to differentiate the level
of hypoxia, as reflected by intensity of EF5 staining.
A novel protocol was developed, based on the method described
by Primeau et al. [4], which analyzes Ki67 (proliferation) and cleaved
caspase 3 (apoptosis) images to measure the location of these markers
relative to blood vessels. The binarized DiOC7 fluorescence image
was used as the input to Image Pro’s Distance Map filter creating
a new image where each pixel’s intensity represents its distance to the
nearest functional blood vessel in the section (Figure 1, A and B). To
evaluate distributions of cell proliferation and apoptosis relative to
functional blood vessels, Ki67 and cleaved caspase 3 bright-field
images were thresholded for positive staining and binarized images
(masks) were created. The Ki67 or cleaved caspase 3 mask was com-
bined with the distance map using a pixel-by-pixel logical “AND”
function, thereby creating a unique image where black regions (zero
intensity) contain no Ki67, and nonzero regions are positive for Ki67
with the intensity values representing the distance to the nearest blood
vessel rather than the usual staining intensity (Figure 1C ).
Because solid tumors are three-dimensional, blood vessels out of
the plane of the tissue sections might confound the above analysis,
especially for quantification of cellular properties in regions distal to
blood vessels in a section. Therefore, Ki67 staining was also evaluated
in relation to the nearest hypoxic region (identified by EF5) to obtain
a more accurate distribution of cell proliferation in regions distal
from functional blood vessels. The EF5 fluorescence image was con-
verted to a black and white binarized image (mask), which was used
to generate a map of distances between pixels and regions of hypoxia.
The distance map was combined with the corresponding Ki67 mask
to determine the mean frequency of Ki67-positive pixels at distances
from the nearest region of hypoxia.
Data are represented graphically as the mean frequency of Ki67/
cleaved caspase 3–positive pixels (normalized for area) at each dis-
tance (0-100 μm) from the nearest blood vessel or region of hypoxia.
Statistical Analysis
For total and functional tumor vasculature and hypoxia, t tests
were performed to determine the significance of differences between
groups. Linear regression was used to evaluate the distributions of cell
proliferation and apoptosis, as a function of distance to the nearest
blood vessel (or hypoxic region). The slopes and Y-intercepts (i.e.,
the perivascular levels) were calculated and compared for all tumor
samples. Differences in the slope and Y-intercepts indicated changes
in the spatial distribution of the measured marker (e.g., Ki67 for
cell proliferation) in relation to functional blood vessels. A one-way
ANOVA, followed by Tukey post hoc test, determined statistical
Figure 2. The effect of paclitaxel (10-30 mg/kg i.p. once every 5 days for three total doses) on (A) growth of A431 xenografts in nude mice
and (B) growth of MCF-7 xenografts in nude mice (points indicate mean for 5 mice per group; bars, SE). The effect of gefitinib (50 or
100 mg/kg by oral gavage, 3 d/wk for 2 weeks) on the growth of (C) A431 (points indicate mean of two independent experiments, 10 mice
per group; bars, SE) or (D) MCF-7 (points indicate mean of 5 mice per group; bars, SE) xenografts in nude mice.
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differences between treatment groups. P < .05 was used to indicate
statistical significance; all tests were two sided.
Results
Effects of Paclitaxel and Gefitinib on Growth of Xenografts
There were dose-dependent effects of paclitaxel on A431 tumor
growth with no significant loss of body weight of the mice for the
range of doses evaluated (Figure 2A). MCF-7 xenografts grew more
slowly than A431 xenografts, and paclitaxel caused greater delay in
their growth (Figure 2B).
Gefitinib inhibited growth of A431 (EGFR+++) xenografts in a dose-
dependentmanner (Figure 2C ), but therewas rapid regrowth of the tumor
once gefitinib treatment was stopped (data not shown). As expected, there
was no effect of gefitinib to inhibit the growth of low EGFR-expressing
MCF-7 xenografts compared with control tumors (Figure 2D).
Figure 3. (A) Photomicrographs of tumor blood vessels after a single dose of paclitaxel (25 mg/kg, i.p.) in A431 xenografts (red = CD31
[total vessels], yellow = DiOC7 [functional vessels]); day 0 = untreated tumors. (B) The number of total and functional blood vessels.
(C) The percentage of functional tumor vasculature. (D) The percentage of hypoxia. *Statistical significance (P < .05) between groups.
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Changes in Vasculature and Hypoxia after Treatment of
Xenografts with Paclitaxel or Gefitinib
The concentration of blood vessels (as measured by CD31 staining)
per tumor area decreased after paclitaxel treatment and was significantly
lower in A431 tumors on days 4 and 12 comparedwith untreated tumors
(Figure 3, A and B; P = .007 and P = .004, respectively). There was a
significant decrease in the number of functional blood vessels per tumor
areameasured 4 days after paclitaxel (Figure 3B; P = .0001) followed by a
rebound on days 8 and 12 (Figure 3B; day 4 vs day 12, P = .01), although
the number of functional vessels remained lower than in untreated
tumors. The percentage of functional blood vessels in A431 xenografts
on days 4 and 8 after paclitaxel treatment was lower than in untreated
tumors (Figure 3,A andC ; P = .006 and P = .008, respectively), followed
by a rebound at 12 days. There was a trend to decreased hypoxia (per
Figure 4. (A) Photomicrographs of tumor blood vessels in A431 xenografts treated with gefitinib (100 mg/kg, days 0-3; red = CD31,
yellow = DiOC7). (B) The number of total and functional blood vessels. (C) The percentage of functional tumor vasculature. (D) The
percentage of hypoxia. *Statistical significance (P < .05) between groups.
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tumor area) in tumors taken on day 8 when compared with untreated
controls (P = .07) followed by a rebound on day 12 (Figure 3D).
Three days of gefitinib treatment caused a decrease in the total
number of blood vessels (i.e., CD31-positive vessels; P < .05) and
in the total number of functional blood vessels per tumor area in
A431 tumors on days 4 and 8 compared with untreated tumors (P <
.05; Figure 4, A and B). However, there was no significant change in
the percentage of functional vessels compared with untreated tumors
(Figure 4, A and C ; P > .05). There was an increase in the percentage
of hypoxia on day 8 (i.e., 5 days after the last dose of gefitinib) com-
pared with untreated controls (Figure 4D; P = .01), likely related to the
observed decrease in perfused vessels.
Treatment of MCF-7 xenografts with either paclitaxel or gefitinib
led to no significant changes in total blood vessels or in the percentage
of functional vasculature. There was a transient increase in hypoxia in
MCF-7 xenografts on day 3 after paclitaxel or gefitinib treatment
compared with untreated tumors (data not shown).
Effect of Paclitaxel on the Distribution of Cell Proliferation
and Apoptosis in Xenografts
There was a high intensity of Ki67 staining in untreated A431
xenografts, and cell proliferation decreased with increasing distance
from the nearest functional blood vessel (Figures 5 and 6A). The
maximum Ki67 staining at ∼20 μm from the nearest blood vessel
likely represents perivascular tumor cells.
At 4 and 8 days after a single 25-mg/kg dose of paclitaxel, there
was a decrease in cell proliferation in regions close to blood vessels
and in intermediate regions (Figure 6A; P < .05). On day 12 after pac-
litaxel treatment, there was a rebound in Ki67 staining (Figure 6A;
day 8 vs day 12, P < .05). There was a low level of Ki67 staining near
hypoxic regions in untreated tumors, and cell proliferation increased
with greater distance from hypoxic regions (Figure 6B). Cell prolifera-
tion remained low near hypoxic regions on days 4 and 8 after paclitaxel
treatment, but by day 12, there was a substantial increase in the prolif-
eration of cells near hypoxic regions, indicating repopulation from these
formerly quiescent cells (Figure 6B; P < .05).
There were few apoptotic cells in untreated A431 tumors with min-
imal dependence on distance from functional blood vessels (Figures 5
and 6C). There was an increase in apoptotic cells staining for cleaved
caspase 3 in regions proximal and distal from functional blood vessels
on day 12 after paclitaxel treatment when compared with untreated
tumors (Figure 6C ). An increase in the necrotic fraction was also noted
in day 8 and day 12 tumors compared with untreated controls.
Analysis of MCF-7 tumor sections showed a relatively uniform
distribution of cell proliferation and cell death (as measured by the
necrotic fraction because MCF-7 cells do not express caspase 3) in
untreated tumors with no significant change in these distributions
after a single 25-mg/kg dose of paclitaxel (data not shown).
Effect of Gefitinib on the Distribution of Cell Proliferation and
Apoptosis in Xenografts
On day 4 (i.e., 1 day after the end of 3 days of gefitinib treatment),
there was a significant decrease in the level of Ki67 staining in re-
gions proximal to functional blood vessels followed by a rebound
in tumor samples taken on day 8 (Figure 7A; P < .01 for day 0 vs
day 4 and for day 4 vs day 8). There was an increase in apoptosis
in A431 tumors on days 4 and 8 when compared with untreated
tumors and the level of cleaved caspase 3 staining was higher in re-
gions more distal to functional blood vessels after gefitinib treatment
(Figure 7B; P < .05).
In MCF-7 tumors, there was an increase in cell proliferation near
blood vessels on day 3 of gefitinib treatments, but by day 5, cell pro-
liferation decreased to levels similar to untreated controls. There was
no change in the distribution of cell death after gefitinib treatment
(data not shown).
Discussion
Repopulation of surviving tumor cells after chemotherapy is likely to
be influenced by many factors within the tumor microenvironment,
including the distribution of drug within the tumor tissue, and
changes in tumor vasculature and hypoxia. Here we show that, after
treatment of A431 xenografts with paclitaxel, there was an initial
decrease in the percentage of functional blood vessels followed by
a partial recovery (Figure 3C ). Similarly, there was a decrease in cell
proliferation in tumor regions close to blood vessels, but prolifera-
tion increased at 12 days after treatment and was observed in regions
Figure 5. The distribution of proliferating (blue, left panel) or apop-
totic cells (yellow, right panel) in relation to functional blood ves-
sels (red) and regions of hypoxia (green) in A431 xenografts on
days 0 (untreated), 4, 8, and 12 after paclitaxel treatment. Scale
bars, 100 μm.
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both proximal to blood vessels and among cells in and adjacent to
hypoxic regions (Figure 6, A and B). The effect of paclitaxel on cell
proliferation could be two-fold: 1) an initial decrease in cell prolif-
eration in regions proximal to blood vessels due to cytotoxic and
cytostatic effects of paclitaxel, which is likely well distributed to
proximal regions; and 2) effects of paclitaxel to decrease functional
vasculature. With less functional vasculature, there is likely a sub-
sequent decrease in oxygen and nutrients available to cells within
the tumor, which could lead to inhibition of cell proliferation and
to cell death [10,12–14].
Figure 6. The effect of a single dose of paclitaxel (25 mg/kg) on cell proliferation in A431 xenografts, as measured by Ki67 staining in
relation to distance from the nearest (A) functional blood vessel and (B) hypoxic region. (C) Effect of paclitaxel on apoptosis, as mea-
sured by cleaved caspase 3 staining, in relation to distance from the nearest functional blood vessel. Lines indicate the mean of four to
six tumors per treatment group; error bars, SE.
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Figure 7. The effect of gefitinib (100 mg/kg by oral gavage, 3 days of treatment) on (A) cell proliferation (Ki67) and (B) apoptosis (cleaved
caspase 3) in A431 xenografts. Time is measured from the start of the gefitinib treatments (i.e., day 4 is 1 day after the last treatment).
Photomicrographs: blue = Ki67, yellow = cleaved caspase 3, and red = functional blood vessels. Plots indicate the frequency of pos-
itively stained pixels in relation to distance from the nearest functional blood vessel. Lines indicate the mean of four to six tumors per
treatment group; error bars, SE.
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Despite the importance of repopulation in the design of optimal
chemotherapy for solid tumors, we are aware of only one prior study
that has shown that the process may originate largely from regions
distal from functional vasculature, in essence rescuing tumor cells
that would have died in the absence of treatment; this is in stark con-
trast to the study of repopulation after radiotherapy where repopula-
tion from surviving hypoxic tumor cells is well established. Huxham
et al. [2] described the distribution of repopulation in human colo-
rectal carcinoma xenografts after treatment with gemcitabine. They
showed that repopulation commenced in regions further from blood
vessels approximately 6 days after gemcitabine treatment [2]. Studies
by Shaked et al. [15] showed that some drugs, including paclitaxel,
decrease microvascular density, whereas others, including gemcita-
bine, have little or no effect. Here we have characterized the effect
of the widely used anticancer drug, paclitaxel, on the spatial distribu-
tion of repopulation in solid tumors. Our data suggest that the
rebound in the percentage of functional tumor vessels in A431 xeno-
grafts approximately 12 days after paclitaxel treatment might be asso-
ciated with a corresponding rebound in cell proliferation (Figures 3C
and 6, A and B). Changes in functional blood vessels are more impor-
tant than changes in total blood vessels, highlighting the importance
of using perfusion markers in conjunction with CD31 staining;
CD31 is expressed on endothelial cells but does not provide informa-
tion on vessel function [16]. Improved availability of nutrients could
stimulate repopulation of the tumor cells [17]. The rebound in pro-
liferation of cells close to regions of hypoxia is particularly noteworthy
on day 12 (Figure 6B ), and this might be due to better access to
nutrients and/or the proliferation of previously quiescent populations.
The observed discrepancy in hypoxic fractions after paclitaxel or
gefitinib treatment (despite similar antivascular effects) could be
due to the higher proportion of cell death noted after paclitaxel com-
pared with gefitinib treatment; the increased cell loss might promote
reoxygenation through decreased oxygen consumption (due to fewer
surviving cells) and improved access of surviving cells to blood vessels
after the removal of dead cells proximal to vessels [18].
The concentration of cells within solid tumors may affect vascular
perfusion and might be modified after chemotherapy [17]. Griffon-
Etienne et al. [17] showed an increase in blood vessel diameter and
vascular flow (as measured by red blood cell velocity) at 2 to 4 days
after paclitaxel treatment of human soft tissue sarcoma xenografts;
this was likely due to an increase in cell death surrounding blood
vessels leading to a reduction in the number of collapsed vessels. Like-
wise, Kuh et al. [19] observed apoptosis 24 hours after treatment,
which corresponded to an observed increase in penetration of pacli-
taxel within the tumor. Our data show an increase in apoptosis and
necrosis after paclitaxel treatment in A431 xenografts (Figure 6C ).
Changes in apoptosis seem to correlate with the rebound in prolifer-
ation after paclitaxel treatment, particularly in distal regions at later
time points (i.e., day 12 tumors)—apoptosis observed in distal cells
could be due to cytotoxic effects or inadequate nutrients before tumor
excision, whereas simultaneous proliferation in distal regions could
stem from a population of cells that did not undergo apoptosis
because of resistance mechanisms or a previously quiescent state pro-
tecting the cell from cytotoxicity from paclitaxel treatment. Apoptosis
probably contributes only to a small fraction of cell death after chemo-
therapy for solid tumors [20,21]; however, recent data suggest that
apoptosis, and specifically activated caspase 3, may be associated with
stimulation of repopulation after radiotherapy [22], and this may also
occur after chemotherapy. This might explain the limited repopulation
observed after treatment of caspase 3–deficient MCF-7 xenografts
with paclitaxel.
In the present study, we have used a novel computer-based image
analysis program to quantify cell proliferation and apoptosis in rela-
tion to blood vessels and hypoxia in tumor sections. This method
overcomes some of the limitations associated with older methods
including its ability to quantify cell proliferation (Ki67) and apopto-
sis (cleaved caspase 3) as binary measurements. Also we analyzed the
whole tumor section rather than averaging results from multiple
smaller areas of interest, thereby avoiding bias associated with select-
ing areas of interest (Figure 1).
Targeted agents might be used to inhibit repopulation in solid
tumors between courses of chemotherapy. An ideal inhibitor is fast
acting and has effects to inhibit tumor cell proliferation that are not
prolonged once the inhibitor is removed, thus allowing cells to reenter
cycle before the next course of cycle-active chemotherapy. Gefitinib
inhibited proliferation of EGFR-overexpressing A431 xenografts
in regions both proximal and distal to functional blood vessels
(Figure 7A). Cell proliferation rebounded by day 8, approximately
5 days after the last dose of gefitinib was administered (Figure 7A ).
Gefitinib has antiangiogenic properties and can inhibit endothelial
cell proliferation [23–25]. There were moderate effects of gefitinib to
change the percentage of functional vessels (Figure 4C ), which could
account for the more rapid rebound in cell proliferation near perfused
vessels after gefitinib compared with treatment with paclitaxel.
Clinically, EGFR inhibitors such as gefitinib and erlotinib have
shown some effects to prolong survival or delay tumor progression
when used alone [26–28], but have had minimal benefit when used
concurrent with chemotherapy compared with chemotherapy alone
[29–31]. It is possible that treatment scheduling played a role in the
negative outcome of these clinical trials because cells might have
been out of cycle because of inhibition of growth due to the EGFR
inhibitor, thereby rendering them less susceptible to cycle-active
chemotherapy. We report elsewhere that gefitinib administered
sequentially between courses of paclitaxel can inhibit repopulation
of A431 cells [32], but determining an optimal schedule in vivo is
likely to be complex and should take into account effects on the
microenvironment, including changes in the functional tumor vas-
culature and in hypoxia. It is likely that combining chemothera-
peutic agents and targeted agents that affect tumor vasculature
will result in antiproliferative, as well as antivascular effects, that can
impact the occurrence and distribution of repopulation in solid tumors.
In summary, we have used a novel quantitative method to detect
changes in the distribution of repopulation in solid tumors. We have
shown that repopulation occurs in A431 xenografts after paclitaxel
treatment and that proliferation of surviving cells occurs in regions
both proximal and distal to functional blood vessels. Furthermore,
our study highlights the interaction between repopulation and
changes in functional blood vessels. Gefitinib has the potential to
inhibit repopulation between courses of chemotherapy due to its
ability to decrease cell proliferation during drug treatment while also
allowing cells to reenter cycle soon after removal of the drug. Gefi-
tinib administered sequentially between courses of paclitaxel might
be effective in inhibiting repopulation of tumor cells.
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Figure W1. EGFR expression in (A) human squamous cell carci-
noma (A431) and human breast cancer (MCF-7) cells and (B) A431
and MCF-7 xenografts.
